Live Breaking News & Updates on அல்லாத ஹாட்ஜ்கின் லிம்போமா|Page 3

Stay updated with breaking news from அல்லாத ஹாட்ஜ்கின் லிம்போமா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

RESILIENCE project aims to reduce the burden of cardiovascular disease in cancer survivors


RESILIENCE project aims to reduce the burden of cardiovascular disease in cancer survivors
Cancer patients are a vulnerable population prone to develop cardiovascular complications. Among other factors, some anticancer therapies can induce adverse cardiovascular effects. Every year, more than 3 million Europeans receive anthracyclines alone or in combination with other anticancer agents. Anthracyclines are a frequently prescribed anticancer agent that can induce an irreversible toxic effect on the heart may lead to chronic heart failure in  ≈5% of the cases. It is estimated that in Europe the prevalence of chronic heart failure secondary to cancer therapy-related cardiotoxicity is ≈1 million people. The trade-off between cancer and chronic heart failure is a massive psychological burden. For healthcare systems, the growing incidence of chronic heart failure has devastating consequences. ....

Borja Ib , Sophia Antipolis , Emily Henderson , Lymphoma Coalition Europe , Council Of Cardio , European Society Of Cardiology , Spanish National Centre For Cardiovascular Research , European Commission , Demographic Change , Spanish National Centre , Cardiovascular Research , Non Hodgkin Lymphoma , Principal Investigator Coordinator , Mobile App , European Society , European Manager , போர்ஜ இப் , எமிலி ஹென்டர்சன் , லிம்போமா கூட்டணி யூரோப் , ஐரோப்பிய சமூகம் ஆஃப் இருதயவியல் , ஸ்பானிஷ் தேசிய மையம் க்கு இருதய ஆராய்ச்சி , ஐரோப்பிய தரகு , மக்கள்தொகை மாற்றம் , ஸ்பானிஷ் தேசிய மையம் , இருதய ஆராய்ச்சி , அல்லாத ஹாட்ஜ்கின் லிம்போமா ,

RESILIENCE, a project to reduce prevalence of heart failure in cancer survivors


European Society of Cardiology
Madrid, 30 June 2021. Cancer patients are a vulnerable population prone to develop cardiovascular complications. Among other factors, some anticancer therapies can induce adverse cardiovascular effects. Every year, more than 3 million Europeans receive anthracyclines alone or in combination with other anticancer agents. Anthracyclines are a frequently prescribed anticancer agent that can induce an irreversible toxic effect on the heart may lead to chronic heart failure in ≈5% of the cases. It is estimated that in Europe the prevalence of chronic heart failure secondary to cancer therapy-related cardiotoxicity is ≈1 million people. The trade-off between cancer and chronic heart failure is a massive psychological burden. For healthcare systems, the growing incidence of chronic heart failure has devastating consequences. ....

Borja Ib , Lymphoma Coalition Europe , Council Of Cardio , European Society Of Cardiology , Spanish National Centre For Cardiovascular Research , European Commission , Demographic Change , Spanish National Centre , Cardiovascular Research , Non Hodgkin Lymphoma , Principal Investigator Coordinator , Mobile App , European Society , European Manager , போர்ஜ இப் , லிம்போமா கூட்டணி யூரோப் , ஐரோப்பிய சமூகம் ஆஃப் இருதயவியல் , ஸ்பானிஷ் தேசிய மையம் க்கு இருதய ஆராய்ச்சி , ஐரோப்பிய தரகு , மக்கள்தொகை மாற்றம் , ஸ்பானிஷ் தேசிய மையம் , இருதய ஆராய்ச்சி , அல்லாத ஹாட்ஜ்கின் லிம்போமா , கைபேசி செயலி , ஐரோப்பிய சமூகம் , ஐரோப்பிய மேலாளர் ,

Bayer: US judge rejects Roundup cancer lawsuits plan | News | DW


Bayer: US judge rejects Roundup cancer lawsuits plan
The German chemical giant may now consider pulling the weedkiller from sale, but maintains that Roundup s main ingredient glyphosate is safe.
Bayer will review the future of glyphosate-based weedkillers in the US market
US district judge Vincent Chhabria on Wednesday rejected a $2 billion (€1.64 billion) plan set up by German firm Bayer to settle future lawsuits over its controversial Roundup weed killer product.
Thousands of Roundup users have claimed the product gave them Non-Hodgkin Lymphoma (NHL), a type of blood cancer.
What did the judge say about the plan?
Chhabria said parts of the plan are  clearly unreasonable and claimed the proposal could not be salvaged by mere tweaks. ....

International Agency For Research On Cancer , Us Environmental Protection Agency , Vincent Chhabria , Non Hodgkin Lymphoma , Protection Agency , International Agency , வின்சென்ட் சாப்ரியா , அல்லாத ஹாட்ஜ்கின் லிம்போமா ,